11:14 AM EST, 02/27/2025 (MT Newswires) -- Cassava Sciences ( SAVA ) said Thursday it has entered into a license agreement with Yale University for intellectual property rights, including an exclusive US method of treatment patent covering simufilam as a potential treatment for seizures linked to rare neurodevelopmental disorders such as tuberous sclerosis complex.
The licensed patent is based on research and development carried out by a neurosurgery professor at Yale, which showed that Cassava's drug candidate, simufilam, reduced TSC-related seizure frequency in animal models.
Shares of Cassava Sciences ( SAVA ) were up more than 12% in recent Thursday trading.
Price: 2.58, Change: +0.28, Percent Change: +12.13